The Role of Timing of Progression and Early Salvage Surgery in Unresectable Hepatocellular Carcinoma Treated with TACE Plus TKIs and PD-1 Inhibitors

被引:0
|
作者
Li, Xingzhi [1 ,2 ]
Tang, Zhihong [1 ]
Pang, Qingqing [1 ]
Wang, Xiaobo [1 ]
Bai, Tao [1 ]
Chen, Jie [1 ]
Wei, Meng [1 ]
Wei, Tao [1 ]
Li, Lequn [1 ]
Wu, Feixiang [1 ,3 ]
机构
[1] Guangxi Med Univ, Canc Hosp, Dept Hepatobiliary Surg, Nanning 530021, Peoples R China
[2] Nanchong Cent Hosp, Clin Coll 2, North Sichuan Med Coll, Dept Hepatobiliary Surg, Nanchong, Peoples R China
[3] Guangxi Med Univ, Key Lab Early Prevent & Treatment Reg High Frequen, Minist Educ, Nanning, Peoples R China
基金
中国国家自然科学基金;
关键词
Hepatocellular carcinoma; salvage surgery; early tumor progression; post-progression survival; real-world; CHEMOEMBOLIZATION; SURVIVAL;
D O I
10.2147/JHC.S481816
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: The prognosis of initially unresectable hepatocellular carcinoma (iuHCC) has been improved by TACE with TKIs and PD-1 inhibitors (TTP). However, the role of timing of tumor progression and and early salvage surgery during TTP therapy remains unclear. Patients and Methods: The data of 151 patients who received TTP for iuHCC consecutively between November 2019 and December 2022 were retrospectively analyzed. The X-Tile software was used to determine the optimal threshold of progression timing to differentiate the post-progression survival (PPS) for patients with tumor progression, ultimately yielding 9 months as the optimal cut-off time. Early tumor progression was defined as patients with tumor recurrence (surgical patients) or progressive disease by mRECIST (nonsurgical patients) within 9 months of initial treatment. Accordingly, early salvage surgery was defined as salvage surgery performed within 9 months of the initial treatment. Results: Out of all the patients, 55 (36.4%) patients showed early tumor progression, 33 (34.4%) showed late tumor progression, and 63 (41.7%) showed non-progression. Patients who experienced early tumor progression had a median PPS of 5.2 months, while those with late tumor progression had a median PPS of 16.8 months (P < 0.001). Multivariable analysis revealed a robust independent correlation between early tumor progression and PPS (HR = 3.279, 95% CI: 1.591-6.756; P = 0.001). Patients who received early salvage surgery showed a considerably lower early tumor progression rate when compared with patients who did not receive early surgery (12.5% vs 42.9%, P = 0.002). The multivariable analysis revealed that early salvage surgery was an independent factor influencing early tumor progression (OR = 0.246; 95% CI: 0.078-0.773; P = 0.016). Conclusion: Early tumor progression is associated with worse PPS in patients with iuHCC receiving TTP therapy. Early salvage surgery can further improve patient outcomes by lowering the incidence of early progression.
引用
收藏
页码:1641 / 1652
页数:12
相关论文
共 50 条
  • [31] Is TACE plus tyrosine kinase inhibitors and immune checkpoint inhibitors superior to TACE plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: the debate continues
    Yang, Shiye
    Liang, Huoqi
    Li, Xing
    Qian, Jiayi
    Ming, Zhibing
    HEPATOLOGY INTERNATIONAL, 2024, 18 (04) : 1336 - 1337
  • [32] Impact of Timing the Combination of Radiotherapy and PD-1 Inhibitors on Outcomes in Patients with Hepatocellular Carcinoma
    Zhong, Liting
    Peng, Weiwei
    Sun, Jingyuan
    Luo, Yongyi
    Sheng, Hailong
    Wu, Yi
    Zhou, Tonggang
    Zhou, Chaoming
    Cao, Chuanhui
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2025, 12 : 123 - 134
  • [33] Prognostic model for unresectable hepatocellular carcinoma treated with dual PD-1 and angiogenesis blockade therapy
    Mo, Zhiqiang
    Lv, Ling
    Mai, Qicong
    Li, Qiao
    He, Jian
    Zhang, Tao
    Xu, Jingwu
    Fang, Jiayan
    Shi, Ning
    Gou, Qing
    Chen, Xiaoming
    Zhang, Jing
    Zhuang, Wenhang
    Jin, Haosheng
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (01)
  • [34] Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors
    Zhao, Yanan
    Wu, Di
    Yao, Quanjun
    Yuan, Hang
    Hu, Hongtao
    Li, Hailiang
    CENTRAL EUROPEAN JOURNAL OF IMMUNOLOGY, 2024, 49 (02) : 147 - 154
  • [35] PD-L1 inhibitor versus PD-1 inhibitor plus bevacizumab with transvascular intervention in unresectable hepatocellular carcinoma
    Huang, Zhenkun
    Chen, Tiejun
    Li, Wenbin
    Qiu, Jiliang
    Liu, Shaoru
    Wu, Zongfeng
    Li, Binkui
    Yuan, Yunfei
    He, Wei
    CLINICAL AND EXPERIMENTAL MEDICINE, 2024, 24 (01)
  • [36] Could the TAE score predicting the prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors be better if certain revisions are made?
    Ma, Xijing
    Lu, Geng
    HEPATOLOGY INTERNATIONAL, 2025, : 484 - 485
  • [37] Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma
    Xin, Yujing
    Zhang, Xinyuan
    Liu, Ning
    Peng, Gang
    Huang, Xiaoyu
    Cao, Xiaojing
    Zhou, Xiang
    Li, Xiao
    HEPATOLOGY INTERNATIONAL, 2023, 17 (03) : 753 - 764
  • [38] Efficacy and safety of lenvatinib plus PD-1 inhibitor with or without transarterial chemoembolization in unresectable hepatocellular carcinoma
    Yujing Xin
    Xinyuan Zhang
    Ning Liu
    Gang Peng
    Xiaoyu Huang
    Xiaojing Cao
    Xiang Zhou
    Xiao Li
    Hepatology International, 2023, 17 : 753 - 764
  • [39] The clinical significance of sarcopenia in patients with hepatocellular carcinoma treated with lenvatinib and PD-1 inhibitors
    Sun, Wei
    Yin, Xue
    Liu, Xiaomin
    Wei, Jianying
    Yu, Minghua
    Li, Wendong
    Ding, Xiaoyan
    Chen, Jinglong
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [40] Pretreatment CT-based machine learning radiomics model predicts response in unresectable hepatocellular carcinoma treated with lenvatinib plus PD-1 inhibitors and interventional therapy
    Wu, Xuewei
    You, Jingjing
    Zhang, Shuixing
    Zhang, Bin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (09)